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The molecular pathogenesis of cholangiocarcinoma (CC) remains unclear.  β-Catenin
functions in both intercellular adhesion and signal transduction.  As a signaling molecule,
mutations in exon 3 of the β-catenin gene encoding the regions phosphorylated by glyco-
gen synthase kinase (GSK)-3β stabilize this protein in cytoplasm.  Subsequently, accumu-
lated β-catenin protein translocates to nuclei and up-regulates the transcriptional activity
of genes involved in oncogenesis.  Recently, mutations in exon 3 of the β-catenin gene
were detected in various carcinomas.  Using polymerase chain reaction (PCR)-single-
strand conformational polymorphism (SSCP) analysis, direct sequencing and sub-
cloning-sequencing, we investigated mutations of exon 3 of the β-catenin gene in CC.
Mutations were found in 26 out of 33 (78.8%) CC tumor samples.  All of the mutations
were heterozygous 1-base deletions at codon 15, resulting in a stop codon at codon 46.
This is the first study demonstrating the presence of β-catenin gene mutations in CC.
However, it was suggested that this mutation might not be involved in deregulation of
β-catenin signaling, because no correlation was observed between the β-catenin mutation
and immunolocalization of β-catenin protein.
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Cholangiocarcinoma (CC) is an intrahepatic
bile duct carcinoma, and is thought to arise
from cholangiocytes or liver stem cells (Sell et
al., 1989).  The molecular mechanism for its
carcinogenesis is poorly understood, although
some studies demonstrating mutations of p53 or
K-ras have been reported in CC (Tada et al.,
1992; Tsuda et al., 1992; Kang et al., 1999).
β-Catenin, the vertebrate homologue of
armadillo protein in Drosophila, is a multifunc-
tional protein involved in cell-cell adhesion
regulation coupled with E-cadherin (Ozawa et
al., 1989) and the Wnt-Wingless developmental
signal-transduction pathway (Gumbiner, 1995).
Disruption of this pathway has been suggested
in tumorigenesis.  In the absence of Wnt signal-
ing, β-catenin is assembled with adenomatous
polyposis coli (APC), axin and glycogen syn-
thase kinase (GSK)-3β and is phosphorylated at
exon 3, coding NH2 terminal serine/threonine
residue by GSK-3β and is subjected to degra-
dation by the ubiquitin-proteasome system
(Aberle et al., 1997).  Activation of the Wnt sig-
nal pathway inhibits GSK-3β and subsequently
induces β-catenin stabilization.  Unphosphor-
ylated β-catenin will not be subjected to ubiqui-
tination and accumulate in cells.  β-Catenin
translocates to the nucleus with T cell factor
(Tcf)/lymphoid enhancer factor (LEF) family
members and activates transcription of target
genes in cell growth control and apoptosis such
as c-myc (He et al., 1998) and cyclin D1 (Tetsu
and McCormick, 1999).  Mutations in the β-
catenin gene have been reported in various
human tumors and cell lines.  The first studies
demonstrated mutations at the GSK-3β phos-
phorylation site in colon cancers (Morin et al.,
1997) and melanoma cell lines (Rubinfeld et al.,
1997).  In colon cancers, expression of the β-
catenin protein in the nucleus increased in
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tumors with either APC mutations or β-catenin
mutations at the GSK-3β phosphorylation site,
because mutations of APC or β-catenin pre-
vented the degradation of β-catenin (Morin et
al., 1997; Sparks et al., 1998).  Similar muta-
tions in exon 3 of β-catenin have been demon-
strated in other cancers and cancer cell lines,
including endometrial carcinoma (Kobayashi
and Sagae, 1999), thyroid carcinoma (Garcia-
Rostan et al., 1999), medulloblastoma (Zurawel et
al., 1998), hepatocellular carcinoma (Miyoshi
et al., 1998), hepatoblastoma (Koch et al., 1999)
and colorectal cell lines (Ilyas et al., 1997).  Nu-
clear and cytoplasmic localization of β-catenin
was also reported in endometrial carcinoma
(Kobayashi and Sagae, 1999), thyroid carcino-
ma (Garcia-Rostan et al., 1999), hepatocellular
carcinoma (Van Nhieu et al., 1999), and hepato-
blastoma (Koch et al., 1999).  Therefore it was
suggested that mutations in β-catenin were in-
volved in carcinogenesis.  However, mutations
in the β-catenin gene in CC have never been
investigated.  The purpose of this study was to
examine mutations in exon 3 of the β-catenin
gene in CC.
Materials and Methods
DNA preparation
Genomic DNA was extracted from 33 formalin-
fixed, paraffin-embedded CC tissues.  The age
of the 33 patients ranged from 19 years to 81
years with an average of 65 years, and the male
to female ratio was 6:5.  All tissues of CC were
adenocarcinomas, and they were classified into
well-differentiated CC (14 patients), moderate-
ly-differentiated CC (12 patients) and poorly-
differentiated CC (7 patients).  DNA was also
extracted from peripheral blood of 53 normal
Japanese volunteers.  The paraffin sections
were deparaffinized, and tumor lesions and
nontumor liver tissue adjacent to the tumor
were scratched up separately under dissecting
microscopy (Nikon, Tokyo, Japan).  DNA was
extracted using standard proteinase K digestion
and phenol/chloroform extraction.
PCR/SSCP analysis
Exon 3 of the β-catenin gene was amplified in
two polymerase chain reactions (PCRs) using
intron-based nested primers.  The outside
primers for the first reaction were 5'-CCA ATC
TAC TAA TGC TAA TAC TG-3' and 5'-CTG
CAT TCT GAC TTT CAG TAA GG-3' (Iwao
et al., 1998); the inside primers for the second
reaction were 5'-TCT ACT AAT GCT AAT
ACT GTT TCG-3' and 5'-ATT CTG ACT TTC
AGT AAG GCA ATG-3' (Samowitz et al.,
1999).  The PCR was carried out in a total re-
action volume of 20 µL containing genomic
DNA, 10 pmol of each primer, 250 µmol/L of
each dNTP, 1.5 mmol/L MgCl2 and 0.5 units of
Gene Taq polymerase (Nippon Gene, Tokyo).
The products of the first PCR were used as a
template for the second PCR.  Both reactions
were performed on an ATTO Zymoreactor II
(ATTO, Tokyo) with an initial denaturation
step at 94˚C for 2 min, then 30 cycles at 94˚C
for 1 min, 58˚C for 2 min and 72˚C for 2 min,
and finnaly 1 cycle at 72˚C for 10 min.
A mixture of 2 µL PCR products and 5 µL
denaturing solution (98% formamide, 20 mmol/
L EDTA and 0.001% bromophenol blue) was
heated at 95˚C for 5 min followed by rapid
cooling on ice and electrophoresed on 14%
polyacrylamide gels with 5% glycerol in 1 ×
TBE running buffer at room temperature.  After
electrophoresis, bands were visualized by silver
staining (Sugano et al., 1993).
Sequencing
The PCR products with an aberrant band detect-
ed by SSCP were purified using the QIAquick
PCR Purification Kit (Qiagen, Hilden, Germany)
and were subjected to cycle sequencing using
the BigDye Terminator Cycle Sequencing FS
Ready Reaction Kit (Perkin-Elmer Applied Bio-
systems, Foster City, CA).  Sequencing was per-
formed in both directions and each sequencing
product was run on an ABI PRISM 310 Genetic
Analyzer (Perkin-Elmer Applied Biosystems).
Data were analyzed by SequencingAnalysis 3.0
software (Perkin-Elmer Applied Biosystems).
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The PCR products with deletion detected by
direct sequencing were also subcloned into a
pGEM-T Vector (Promega, Madison, WI).  The
DNA sequence of each clone was determined
using an ALFred sequencer (Amersham
Pharmacia Biotech, Uppsala, Sweden) with a
Cy5 Thermo Sequenase Dye Terminator Kit
(Amersham Pharmacia Biotech).
Reliability of the technique
We performed PCR/SSCP analysis repeatedly
starting with the first PCR in all CC samples.  In
addition, to confirm the reliability of our
technique, we analyzed the β-catenin gene in
thyroid carcinoma (n = 6) in which both frozen
and formalin-fixed materials were available,
using our method.  Moreover, we analyzed the
β-catenin gene in formalin-fixed colorectal car-
cinoma (n = 6), which was thoroughly studied
for β-catenin gene mutation, using our method.
Immunohistochemistry
Immunostaining was performed on 3-µm paraffin
sections with β-catenin monoclonal antibody
(clone 14, immunoglobulin G1 class) purchased
from Transduction Lab (Lexington, KY) using
the antigen retrieval protocol, as previously re-
ported (Ashida et al., 1998).  In each β-catenin
immunostaining, β-catenin expression was
evaluated and the results were semiquantita-
tively categorized into the seven ranging from
+3 to –3 according to the percentage of positive
cells within a tumor area in comparison to a
nontumor area, as previously reported (Ashida
et al., 1998).  A nuclear expression was con-
sidered positive when more than 10% of nuclei
was strongly stained for β-catenin, as previous-
ly reported (Terris et al., 1999).
Statistical analysis
Statistical analysis was performed using Fisher’s
exact test and Mann-Whitney’s U test with a
significant level of P < 0.05.
Results
Exon 3 of the β-catenin gene from CC tumor
and nontumor samples was amplified by PCR
and the resulting PCR products were screened
by SSCP analysis.  Representative SSCP gel
patterns of 3 tumor and nontumor tissues from
CC are shown in Fig. 1.  Aberrant bands were
detected in the majority of tumor samples.  PCR
products with aberrant bands detected by SSCP
analysis were subjected to direct se-
quencing.  The results of direct
sequencing analysis suggested that
the β-catenin gene from tumor sam-
ples with aberrant SSCP bands might
bear heterozygous deletion (Fig. 2a).
By subcloning-sequencing, it was con-
firmed that one allele of the β-catenin
gene had a 1-base pair deletion (A) at
codon 15 and the other was a wild-
type (Fig. 2b).  We detected this muta-
tion in 26 of 33 (78.8%) CC tumor tis-
sues.  Other types of mutations were
not found in this study.  This alteration
was reproducible by repeated analysis
starting with the first PCR.  In both the
frozen and formalin-fixed thyroid car-
cinomas used as controls, there were
no mutations in any cases.  Moreover,
we did not detect any mutations in
Fig. 1.  Single-strand conformational polymorphism analysis
of tumor (T) and nontumor (NT) from cholangiocarcinoma
samples.  Aberrant bands are indicated by the arrow.  Mutations
were detected in the tumor tissues in cases 1 and 3.
TNT NT T TNT
Case 1 Case 3Case 2
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formalin-fixed colorectal carcinoma.  This de-
letion at codon 15 of the β-catenin gene caused
a frameshift that resulted in a stop codon 31
amino acids downstream from the mutation,
thereby producing a truncated peptide (Fig. 3).
Since this mutation was detected in neither
Fig. 2.  Sequencing data of β-catenin exon 3 in cholangiocarcinoma (CC) samples.
a: Electropherograms by direct sequencing showing the sequence of tumor samples with aberrant bands
detected by single-strand conformational polymorphism analysis and wild-type sequence derived from
the control sample.  The possibility of heterozygous 1-base pair deletion is indicated by the arrow.
b: Electropherograms from subcloned polymerase chain reaction products of CC tumor tissues with muta-
tion showing sequences of the wild-type allele and mutant allele.  One-base pair (A) deletion was
detected at codon 15 in mutant allele.
nontumor liver tissue nor peripheral blood from
healthy volunteers (Table 1), it was considered
that this mutation was somatic and might be
related to CC.  To the best of our knowledge,
this is the first study demonstrating the presence
of β-catenin mutations in CC.
Relationships between the β-
catenin mutation and the available
clinicopathological data were de-
termined (Table 2).  No significant
difference was found between the
β-catenin mutation and the clini-
copathological parameters.
Relationships between the β-
catenin mutation and immuno-
localization were also determined
(Table 3).  We previously reported
that membranous expression was
unchanged or decreased in all
cases (Ashida et al., 1998).  In this
study, we reevaluated intracyto-
plasmic and nuclear expression in
CC.  Cytoplasmic staining was ob-
served in 8 cases (24%).  Among
them, 3 cases (9.1%) showed immu-
noexpression in the tumor cell nu-
clei.  Membranous expression in
cases with mutation did not signif-
icantly decrease compared with
that in cases without mutation.  No
correlation was found between β-
catenin mutation and immunohisto-
chemical data.
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NH2 COOH
GSK-3β sites 
 
6–DLMELDMAMEPDRKAAVSHWQQQSYLDSGIHSGATTTAPSLSG–48
1-bp deletion
at codon 15
6–DLMELDMAMDQTEKRLLVTGSNSLTWTLESILVPLPQLLL*–46
stop codon
mutant
wild-type
exon 3
Table 1.  Alterations in the β-catenin gene
        Frequency of deletion
    at codon 15
(%)
Tumor tissues  (CC) 78.7 [26/33]
Nontumor tissues (CC)   0 [  0/33]
Blood (healthy  volunteers)   0 [  0/53]
CC, cholangiocarcinoma.
Table 2.  Correlations between β-catenin mutation and clinicopathological data
     Variable Category No mutation Mutation P value
Tumor grade Well-differentiated CC 4 10 NS
Moderate-differentiated CC 2 10
Poor-differentiated CC 1 6
Vascular invasion Present 5 22 NS
Absent 2 4
Metastasis Present 5 12 NS
Absent 2 14
CC, cholangiocarcinoma; NS, not significant.
Discussion
The most frequent mutations in various cancers
have been shown to result in amino acid sub-
stitutions at several serine or threonine phos-
phorylation sites and flanking residues in the
regulatory degradation targeting region encod-
ed by exon 3 (Ilyas et al., 1997; Miyoshi et al.,
1998; Garcia-Rostan et al., 1999; Kobayashi
and Sagae, 1999; Koch et al., 1999).  Small de-
letions at the GSK-3β phosphorylation site or
larger deletions spanning the whole of exon 3
were also reported in some cancers and all of
them were in-frame mutations (Ilyas et al., 1997;
Rubinfeld et al., 1997; Iwao et al., 1998; Miyoshi
et al., 1998; Koch et al., 1999; Van Nhieu et al.,
1999).  Therefore it was suggested that unphos-
phorylated β-catenin accumulated in cytoplasms
of cells and translocated to the nuclei.  This is
consistent with the data of immunohistochem-
Fig. 3.  Schematic representation of the location of β-catenin mutations in cholangiocarcinoma.  bp, base pair.
ical studies in various carcinomas (Iwao et al.,
1998; Garcia-Rostan et al., 1999; Kobayashi and
Sagae, 1999; Koch et al., 1999; Van Nhieu et al.,
1999).  Mutations in most carcinomas were
found at a frequency of 10 to 30%, although β-
catenin gene alterations in some cancers includ-
ing thyroid carcinoma (Garcia-Rostan et al.,
1999) and hepatoblastoma (Koch et al., 1999)
occurred at a frequency of 50 to 60%.  How-
ever, the mutation detected in this study occur-
red more frequently (78.8%).  Moreover, this
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mutation is a rare frameshift in the coding re-
gion, although mutations resulting in a stop
codon were also detected in some genes, includ-
ing E-cadherin in sporadic lobular breast cancer
(Berx et al., 1996) and p53 in ovarian carci-
noma (Milner et al., 1993).  Although we have
used formalin-fixed tissues in this study, it was
reported that non-reproducible sequence altera-
tions were detected with the use of formalin-
fixed tissues (Williams et al., 1999).  This
alteration was reproducible by repeated analy-
sis starting with the first PCR.  To confirm the
reliability of our technique, we analyzed the β-
catenin gene in thyroid carcinoma and there
were no mutations in both fresh and formalin-
fixed specimens.  In addition, there were no mu-
tations in the β-catenin gene in formalin-fixed
colorectal carcinoma.  Therefore, we consider-
ed that the technique we used was reliable.  Al-
though immunolocalization of β-catenin in CC
tissues has hardly been investigated, we pre-
viously demonstrated that membranous expres-
sion of β-catenin was unchanged or reduced in
CC specimens (Ashida et al., 1998).  Since im-
munolabeling was performed using an anti-β-
catenin monoclonal antibody, raised against the
carboxyl-terminal fragment of β-catenin, it was
suggested that normal β-catenin protein expres-
sed in CC tumor tissues.  In this study, we de-
monstrated cytoplasmic and nuclear expression
in some cases.  However it was considered that
aberrant expression of β-catenin protein was
not associated with the mutation.
In our study, there were no significant dif-
ferences between β-catenin mutations and
clinicopathologic data.  The reason for this is
unclear now, and remains to be clarified in the
future.  It is unclear whether this truncated
protein is stable.  Commercial antibody against
the N-terminal of β-catenin, which is useful for
immunohistochemistry, was not available in
our study.  We also could not perform Western
blot analysis because the corresponding frozen
tissues were not available.  Moreover, we could
not make an antibody against the new protein
sequence.  However, we thought that this pro-
tein might be unstable and would immediately
degrade, because it is a very small protein con-
sisting of 46 amino acids.  It would be interest-
ing to analyze a more related tissue during em-
bryonal development like pancreas carcinoma
as a control; however, it was impossible to
obtain pancreas carcinoma tissues in the present
study.  Because no metastatic lesions of CC
were available, no investigation of β-catenin in
metastatic foci was performed in our study.  For
these subjects, further studies are required.
It was reported that loss of heterozygosity of
APC was detected in CC (23.4%) and the al-
teration of APC might play a role in the tumori-
genesis of CC (Kang et al., 1999).  The altera-
tion of APC might be involved in β-catenin
protein accumulation because APC interacted
with β-catenin in the Wnt signal pathway.  In
addition, other factors such as axin and GSK-β
which were related to the degradation of β-
Table 3.  Relationship between β-catenin mutation and expression of β-catenin protein
Expression of β-catenin protein
        Membranous          Cytoplasmic             Nuclear
0 –1 –2 –3 0 +1 +2 +3 + –
No mutation 3 2 2 0 4 2 0 1 1 6
Mutation 11 7 7 1 21 3 2 0 2 24
0, the same expression as that of non-cancerous bile ducts;
–1, mildly weak expression relative to non-cancerous bile ducts;
–2, moderately weak expression relative to non-cancerous bile ducts;
–3, markedly weak expression relative to non-cancerous bile ducts;
+1, mildly strong expression relative to non-cancerous bile ducts;
+2, moderately strong expression relative to non-cancerous bile ducts;
+3, markedly strong expression relative to non-cancerous bile ducts;
+, nuclear positive expression;
–, nuclear negative expression.
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catenin in the ubiquitin-proteasome system
were considered to be associated with increased
β-catenin protein expression, since it was re-
cently reported that the mutation in AXIN1, an
encoding axin, caused hepatocellular carcino-
ma (Satoh et al., 2000).
In summary, the present study shows for the
first time that somatic mutation in the β-catenin
gene occurs frequently in CC.  However, no cor-
relation was found between the β-catenin mu-
tation and immunolocalization of β-catenin
protein.  Therefore, it was suggested that de-
regulation of β-catenin signaling might not
occur in CC.  Further investigations are requir-
ed to elucidate the role of heterozygous muta-
tion in CC.
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